• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Economic Impact of Vitiligo in the United States

Opinion
Video

Gary M. Owens, M.D., discusses the economic costs associated with vitiligo and the impact this disease has had on the U.S. health care system in general.

Dr. Heather Woolery-Lloyd: Now I want to change gears a little bit and talk about the impact of vitiligo on the U.S. health care system in general. (Dr. Owens), can you tell us a little bit more about the economic costs associated with vitiligo?

Dr. Gary M. Owens: Yes, I can. I can tell you there is a lot that we don’t know about the economic costs of vitiligo. There was a 2018 analysis that went through all the known literature that (the authors) could find. They found exactly two studies on the economic cost of a vitiligo. Actually, in 2004, that one study identified only about $15 million in cost in the U.S. We know that’s probably dramatically understated, partly because it’s very difficult prior to the first approved drug for vitiligo in 2002 to track the cost because most treatments were off label and (it is) almost impossible to track the cost when you have something like corticosteroids that have a myriad of uses. The American Academy of Dermatology published a Skin Disease brief in 2017 that upped that cost to about $49 million, which again I think is very much understated, but they compared it (with) skin infections, which was a whopping $8.1 billion. If you compare that (with) the big three diseases, cancer at $200 billion, diabetes at $237 billion and cardiovascular disease at $320 billion, I think what we’re seeing here is that we don’t know the cost of vitiligo, and it may have a little problem getting attention just because it gets lost in some of those what I will call the thousand-pound-gorilla diseases that we’re looking at.

Dr. Heather Woolery-Lloyd: That’s such a great point, because vitiligo is something that is very difficult to track because prior to the FDA approval of some newer medications, this was something that was treated completely off-label. I do think there (are) some real challenges, as you mentioned, with tracking the economic impacts of vitiligo.

Dr. Gary M. Owens: Right. Literally, no one is doing a lot of economic analysis. Probably room for future research, especially as we get more approved therapies out there.

Dr. Heather Woolery-Lloyd: Yes, I think that is exciting, and I love that we do have this interest, this new interest in vitiligo, because I think it’s a disease that has been “forgotten” for a while or maybe even ignored. This is exciting that we will get more data to understand economic impacts in the future.

Transcript edited for clarity.


Related Videos
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
Video 3 - "Harnessing Prescription Drug Therapeutics as Monotherapy and Adjunct Therapy"
Video 8 - "Demographic Differences That Impact Care"
Video 7 - "Gaps in Diabetes Education and Self Efficacy"
Video 6 - "Developing Reimbursement Models for Digital Therapeutics"
Video 5 - "Cost-Effectiveness Metrics Payers Seek for Digital Therapeutics"
Video 2 - "Bridging Care Gaps with Prescription Digital Therapeutics"
Related Content
© 2024 MJH Life Sciences

All rights reserved.